Mersana Therapeutics Acquired by Day One Biopharmaceuticals, Delisted from Nasdaq

summarizeSummary

Mersana Therapeutics, Inc. has completed its acquisition by Day One Biopharmaceuticals, Inc., becoming a wholly-owned subsidiary, and its common stock has been delisted from Nasdaq.

check_boxKey Events

• Merger Completed

  Day One Biopharmaceuticals, Inc. successfully acquired Mersana Therapeutics, Inc., which is now a direct wholly-owned subsidiary.

• Shareholder Consideration

  Public shareholders received $25.00 per share in cash and one non-tradeable Contingent Value Right (CVR) per share, with CVRs potentially yielding up to an additional $30.25 per share upon achievement of specified milestones.

• Delisting and Deregistration

  Mersana's common stock has been delisted from Nasdaq, and the company will terminate its registration under the Exchange Act, ending its public reporting obligations.

• Board and Management Changes

  All previous directors and incumbent officers of Mersana Therapeutics resigned, with new directors and officers appointed from Day One Biopharmaceuticals.

auto_awesomeAnalysis

This 8-K filing confirms the completion of the merger between Mersana Therapeutics and Day One Biopharmaceuticals. Public shareholders received $25.00 in upfront cash plus one non-tradeable Contingent Value Right (CVR) per share, with potential future payments up to $30.25 per CVR. The company's stock has been delisted from Nasdaq, and its registration terminated, marking the end of its existence as an independent publicly traded entity. This event fundamentally alters the investment thesis for former shareholders, converting their equity into a fixed cash payment and contingent future rights.